Thoughts on value

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

bfw

Rank: Vice President [?]

Points: 840 [?]

Votes: 19 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Follow

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Thoughts on value

posted on Nov 16, 2019 04:09PM

Log in to use the IP Check tool ^[?]

First, let’s consider the market cap of Big Pharma.

Pfizer $206B US

Astra Zenica $123B US

Merck $216B US

etc.

Resverlogix has a market cap of around $300 million US.

If Big Pharma thinks there is any possibility this drug makes it to market on a MACE indication, it seems logical they would be interested.

Based on the results and the Forest Plot specifically, there is a very strong possibility that this drug will be approved at some point.

The big question will be price and deal structure.

Amarin has a market cap over $8 Billion. They also face competition from other players in that space and upcoming trial readouts.

RVX is a minnow that Big Pharma can easily afford to swallow at a hefty premium. We can’t expect $8 Billion but something with a B should work.

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Thoughts on value